Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: Tocilizumab

First Posted Date: 2016-01-06

Last Posted Date: 2019-03-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 200

Registration Number: NCT02648035

Locations: 🇬🇷
Private Practice Rheumatology, Merantzis, Agrinio, Greece
🇬🇷
ATTIKO Hospital_4th University Internal Medicine Clinic, Haidari, Greece
🇬🇷
General Hospital of Mytilini, Rheumatology, Mytilini, Greece

and more 12 locations

A Study of Peginterferon Alfa-2a (Pegasys) When Administered in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC)

Phase 4

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: Peginterferon alfa-2a
Drug: Ribavirin

First Posted Date: 2015-12-29

Last Posted Date: 2016-08-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 737

Registration Number: NCT02641379

Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Cobimetinib

First Posted Date: 2015-12-24

Last Posted Date: 2022-09-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 56

Registration Number: NCT02639546

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
🇺🇸
Arnold Palmer Hosp-Children, Orlando, Florida, United States

and more 14 locations

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) Given by Mouth in Healthy Volunteers

Phase 1

Completed

Conditions: Spinal Muscular Atrophy

Interventions: Other: Placebo
Drug: Risdiplam
Drug: Itraconazole

First Posted Date: 2015-12-17

Last Posted Date: 2018-10-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 33

Registration Number: NCT02633709

Locations: 🇳🇱
Pra International Group B.V, Groningen, Netherlands

A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Phase 1

Completed

Conditions: Lymphoma, Follicular

Interventions: Drug: Atezolizumab (MPDL3280A) [TECENTRIQ]
Drug: Lenalidomide
Drug: Obinutuzumab

First Posted Date: 2015-12-16

Last Posted Date: 2022-04-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 38

Registration Number: NCT02631577

Locations: 🇺🇸
University Miami, Miami, Florida, United States
🇫🇷
Hopital du Bocage, Dijon, France
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

and more 13 locations

Safety, Tolerability and Pharmacokinetics of Oral CellCept (Mycophenolate Mofetil) in Pediatric Liver Transplant Recipients on Concomitant Treatment With Cyclosporine and Corticosteroids

Phase 2

Terminated

Conditions: Pediatric Liver Transplantation

Interventions: Drug: Corticosteroids
Drug: Cyclosporine
Drug: mycophenolate mofetil

First Posted Date: 2015-12-15

Last Posted Date: 2016-05-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 9

Registration Number: NCT02630563

A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)

Phase 2

Completed

Conditions: Muscular Atrophy, Spinal

Interventions: Drug: Olesoxime

First Posted Date: 2015-12-11

Last Posted Date: 2019-08-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 131

Registration Number: NCT02628743

Locations: 🇫🇷
Hopital Femme Mere Enfant; Medecine Physique et Readaptation Pediatrique - L'ESCALE, Bron, France
🇫🇷
Hôpital Raymond Poincare; Serv. Neurologie et Réanimation pédiatriques - Centre réf. neuromusculaire, Garches, France
🇫🇷
Hopital Jeanne De Flandre; CIC pediatrique, Lille, France

and more 21 locations

A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)

Phase 1

Completed

Conditions: Solid Tumor
Cancer of Head and Neck
Breast Cancer

Interventions: Drug: RO6874281
Drug: Trastuzumab
Drug: Cetuximab

First Posted Date: 2015-12-10

Last Posted Date: 2022-11-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 134

Registration Number: NCT02627274

Locations: 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸
UCSD - Moores Cancer Center, La Jolla, California, United States
🇨🇦
Princess Margaret Cancer Center, Toronto, Ontario, Canada

and more 23 locations

Bevacizumab in Metastatic Renal Cancer

Completed

Conditions: Renal Cell Cancer

Interventions: Drug: Bevacizumab
Drug: Interferon alpha-2a

First Posted Date: 2015-12-10

Last Posted Date: 2016-08-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 365

Registration Number: NCT02627144

Health Care Personnel Time for Anemia Management With Erythropoiesis Stimulating Agents in Hemodialysis Centers in Croatia

Completed

Conditions: Renal Anemia of Chronic Kidney Disease

Interventions: Other: No intervention

First Posted Date: 2015-12-09

Last Posted Date: 2016-03-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 110

Registration Number: NCT02625844

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy